Combination treatment for aggressive B-cell lymphoma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of fast-growing B-cell lymphoma (like diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or transformed large B-cell lymphoma).
- Your lymphoma has come back or not responded to at least one previous treatment (including standard chemotherapy and a drug called rituximab).
- You are between 18 and 65 years old.
- You are in generally good health (able to do daily activities with little help) and have adequate blood counts, liver and kidney function.
- You have not had a stem cell transplant before, and do not have active hepatitis B or C, HIV, or other uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new approach to treating aggressive B-cell lymphomas that have returned or didn't respond to initial chemotherapy. It combines a drug called glofitamab with CAR-T cell therapy (immune cells engineered in the lab to fight cancer) to see if it improves outcomes for patients who are candidates for this advanced treatment.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
Hear when a new Relapsed or Refractory Aggressive B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.